证券代码：000534 证券简称：万泽股份 公告编号：2025-100 万泽实业股份有限公司 关于召开 2025 年第五次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第五次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：本次会议的召集、召开符合《中华人 民共和国公司法》《深圳证券交易所股票上市规则》《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、 部门规章、规范性文件及《公司章程》的有关规定。召开本次会议的决定 已经第十一届董事会第五十五次会议审议通过。 4、会议时间： （1）现场会议时间：2025 年 12 月 08 日 14:30。 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体 时间为 2025 年 12 月 08 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为 2025 年 12 月 08 日 9:15 至 15:00 的任意时间 ...

万泽实业股份有限公司（以下简称"公司"）第十一届董事会第五十五 次会议于 2025 年 11 月 20 日以通讯方式召开。会议通知于 2025 年 11 月 17 日以电子邮件方式送达各位董事。公司董事 6 人，实际参会董事 6 人，会 议的召开符合《公司法》及《公司章程》的有关规定。会议决议事项如下： 一、审议通过《关于增补非独立董事的议案》 鉴于毕天晓先生此前因工作变动原因向公司董事会辞去董事兼总经理 职务（公告编号：2024-053），经公司控股股东万泽集团有限公司提名推荐， 并经公司独立董事 2025 年第二次专门会议审查，公司董事会同意增补林伟 光先生（简历附后）为公司第十一届董事会非独立董事候选人，并提交公 司股东会审议，任期为公司股东会审议通过之日起至本届董事会届满之日 止。公司董事会本次增补完成后，公司董事会中兼任公司高级管理人员以 及由职工代表担任的董事人数总计未超过公司董事总数的二分之一。 表决结果：同意：6 票；反对：0 票；弃权：0 票。 本议案尚需提交公司股东会审议。 二、审议通过《关于召开2025年第五次临时股东会的议案》 证券代码：000534 证券简称：万泽股份 公告编号:20 ...

Group 1 - The core point of the article is that Wanze Co., Ltd. announced the convening of its 11th Board of Directors meeting on November 20, 2025, to discuss the proposal for the fifth extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Wanze Co., Ltd.'s revenue composition is as follows: pharmaceutical manufacturing accounts for 72.08%, manufacturing accounts for 26.65%, and other businesses account for 1.27% [1] - As of the time of reporting, Wanze Co., Ltd. has a market capitalization of 10.3 billion yuan [1]

证券代码：000534 证券简称：万泽股份 公告编号:2025-098 万泽实业股份有限公司 关于控股股东可交换公司债券进入换股期的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、控股股东可交换公司债券进入换股期基本情况 本期可交换债券将于 2025 年 11 月 24 日进入换股期。本期可交换债券 换股期限自可交换债券发行结束日满 6 个月后的第一个交易日起至可交换 债券摘牌日的前一交易日止，即 2025 年 11 月 24 日至 2028 年 5 月 19 日止。 1 换股期间，万泽集团所持的本公司股份可能会因投资者选择换股而导致减 少。 二、对公司的影响 截至 2025 年 11 月 18 日，万泽集团及其一致行动人合计持有本公司股 份 165,839,659 股，占本公司目前总股本的 32.56％。进入换股期后，万泽 集团持有的本公司股份可能会因投资者选择换股而减少。经测算，假设全 部债券持有人持有的债券全部用于换股，不会导致公司控制权发生变化， 万泽集团仍为公司第一大股东。 万泽实业股份有限公司（以下简称"公司"或"本公司"）的控股股 ...

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Market Overview - The biopharmaceutical sector experienced a decline of 1.94% on November 17, with Kexing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Bohui Innovation: Closed at 8.00, up 2.56% with a trading volume of 824,300 shares [1] - ST Weiming: Closed at 8.31, up 2.21% with a trading volume of 60,800 shares [1] - Major decliners included: - Kexing Pharmaceutical: Closed at 34.59, down 7.88% with a trading volume of 53,300 shares [2] - Jinwei: Closed at 26.05, down 7.06% with a trading volume of 123,100 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 1.211 billion yuan from institutional investors, while retail investors contributed a net inflow of 893 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Wanzhe Co.: Net outflow of 37.20 million yuan from institutional investors [3] - Olin Bio: Net inflow of 13.81 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different companies within the sector [3]

2025 年 6 月 30 日，公司 2024 年度股东大会审议通过《关于拟向相关 金融机构申请综合授信额度的议案》《关于确定担保额度的议案》等议案， 同意公司（含公司合并报表范围内的下属子公司）向银行等金融机构申请 综合授信业务和与具有相应资质的金融公司合作进行融资业务，并由本公 司或子公司为上述融资业务提供连带责任担保，担保对象为公司及合并报 表范围内的下属子公司，担保方式包括但不限于保证担保、信用担保、资 产抵押、质押等以及因业务需要向相关方视情况提供的反担保，担保额度 不超过 56 亿元，担保额度的授权期限自公司 2024 年度股东大会审议通过 之日至公司 2025 年度股东大会召开之日止，担保额度在授权期限内可循环 使用，担保额度可根据实际情况在公司和下属子公司间进行调剂，其中万 泽航空的额度为 5 亿元，具体内容详见公司相关公告（公告编号：2025-024、 1 证券代码：000534 证券简称：万泽股份 公告编号:2025-097 万泽实业股份有限公司 关于公司为下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、公 ...

Group 1 - The core viewpoint highlights the active performance of innovative drug concept stocks, with notable movements in specific companies [1] - Nanjing Xinbai has achieved two consecutive trading limits, indicating strong investor interest [1] - BeiGene has seen an increase of over 6%, reflecting positive market sentiment towards its stock [1] Group 2 - Other companies such as Hainan Hai Chen Pharmaceutical, Lianhua Technology, Wanze Shares, and Xinlitai have also experienced upward trends, suggesting a broader rally in the sector [1]

Core Viewpoint - The biopharmaceutical sector experienced a slight increase of 0.44% on November 12, with significant gains from specific stocks, while the overall market indices showed a decline [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4000.14, down 0.07% - The Shenzhen Component Index closed at 13240.62, down 0.36% [1] Group 2: Top Gainers in Biopharmaceutical Sector - BGI Innovation (300318) led the gains with a closing price of 7.20, up 20.00% with a trading volume of 651,300 shares and a transaction value of 458 million yuan - Sanyuan Gene (920344) followed with a closing price of 33.15, up 12.45% and a trading volume of 85,300 shares [1] - Other notable gainers include: - Sangfor Biopharma (688336) at 68.50, up 6.60% - Sai Sheng Pharmaceutical (300485) at 12.88, up 4.63% [1] Group 3: Market Capital Flow - The biopharmaceutical sector saw a net inflow of 325 million yuan from institutional investors, while retail investors experienced a net outflow of 317 million yuan [2] - The top stocks by net inflow from institutional investors included: - Sangfor Biopharma (688336) with a net inflow of 136 million yuan - He Yuan Biopharma (688765) with a net inflow of 108 million yuan [3]

Investment Rating - The report does not explicitly state an investment rating for the industry [1] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.4% from November 3 to November 7, 2025, underperforming compared to the Wind All A index (0.63%) and the CSI 300 index (0.82%) [2][7] - The rise in flu activity was noted, with the percentage of flu-like illness (ILI) cases reported at 4.7% in the week of October 27 to November 2, 2025, indicating an increase compared to previous weeks and years [2][10] - The final overall survival (OS) results from the HARMONi-A study of Ivosidenib combined with chemotherapy for EGFR-mutant non-small cell lung cancer showed a significant improvement in OS, with a median OS of 16.8 months versus 14.1 months for the control group [2][10] Weekly Market Review - The pharmaceutical and biotechnology sector's performance was down 2.4%, with notable declines in medical research outsourcing (-4.93%), chemical preparations (-4.42%), and other biological products (-4.33%) [7][8] - The leading gainers included Hezhi China (61.1%), Wanze Shares (30.3%), and Fuxiang Pharmaceutical (23.3%), while Changshan Pharmaceutical (-20%), Yifang Bio-U (-17.8%), and Guangshengtang (-15.3%) were the biggest losers [10] Industry News and Key Company Announcements - On November 7, 2025, the final OS analysis of the HARMONi-A study was presented, showing significant results for Ivosidenib in combination with chemotherapy [10][12] - According to data from the Chinese Center for Disease Control, flu-like illness percentages in southern provinces increased to 4.6%, while northern provinces reported 5.1%, both higher than the previous week [10][12] - BeiGene reported a total revenue of $1.412 billion for Q3 2025, a 41% year-on-year increase, driven by a 51% growth in global sales of its product [12][14] - Metsera announced a merger agreement with Pfizer, with an estimated total transaction value of approximately $9 billion [12][14]